RecruitingNCT06865482
Clinical Course Of Disease In Participants With FA-CM
Characteristics And Clinical Course Of Disease In Participants With Cardiomyopathy Associated With Friedreich Ataxia (CLARITY-FA)
Sponsor
Lexeo Therapeutics
Enrollment
65 participants
Start Date
Sep 30, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)
Eligibility
Min Age: 6 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with cardiomyopathy and friedreich ataxia. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 6 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06865482
Related Trials
Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
NCT068962664 locations
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
NCT064470258 locations
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
NCT0601694634 locations
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
NCT077210251 location
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
NCT011434543 locations